Dr Wen outlines major changes in the recent WHO Classification of Brain Tumors, discussing implications for clinical practice and research.
Update on the 2021 WHO Classification of Brain Tumors: implications for clinical practice and research
Dr Wen has disclosed that he is/was a consultant/advisor for Astra Zeneca, Bayer, Black Diamon, Boerhinger Ingelheim, , Boston Pharmaceuticals, Celularity, Chimerix, Day One Bio, Genenta, Glaxo Smith Kline, Karyopharm, Merck, Mundipharma, Novartis, Novocure, Nuvation Bio, Prelude Therapeutics, Sapience, Servier, Sagimet, Vascular Biogenics, VBI Vaccines. He disclosed that he is/was a research grant recipient from Astra Zeneca, Beigene, Bristol Meyers Squibb, Chimerix, Eli Lily, Erasca, Kazia, MediciNova, Merck, Novartis, Nuvation Bio, Puma, Servier, Vascular Biogenics, VBI Vaccines